Intralinks Holdings, Inc. IL
13.01 +13.01
At closeJun 28, 2019, 6:07 PM EDT
Day range unavailable
52-week range unavailable
No chart data for this range yet.
Financials — quick view
IL Revenue — quarterly 75.41M
IL Net income — quarterly -1.23M
IL EPS — quarterly -0.02
News
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa 
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress 
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis 
AI Use Permeates Dealmaking Despite Operational Concerns: SS&C Intralinks Report 
SS&C Intralinks Predicts M&A Deal Flow Resilience in Q1 2025 
SS&C Intralinks Predicts M&A Deal Flow Rising Globally in Q4 2024 
SS&C Intralinks Releases 2025 Limited Partner Survey Results 
Intralinks Announces Date of Earnings Release and Conference Call for
its Third Quarter 2016 Financial Results 
Intralinks Announces Date of Earnings Release and Conference Call for
its Second Quarter 2016 Financial Results
Your note
Sign in to keep a note on IL — it syncs with the Stock Master app.